Just In Case You Read Little Else Today, Check This Claim Regarding BML-190

7?��?4.7 and 7.9?��?4.4, respectively, p?Selleckchem BMS907351 of BEV for non-squamous NSCLC patients with brain metastases was thought to be contraindication. However, the administration of BEV to those with brain metastases has been shown to be safe from the analysis BML-190 of clinical trials overseas, which terminated the Japanese policy of contraindication. Objective?We retrospectively investigated the efficacy and safety of BEV administration for non-squamous NSCLC patients with brain metastases. Result?Nine cases from January 2010 to May 2012 were analyzed. The patients consist of six men and three women. The median age was 68. Histology showed seven adenocarcinoma and two NSCLCs. Five patients underwent gamma-knife surgery and one patient had whole brain radiation therapy, while three had no specific therapy for the brain metastases. Six cases could be evaluated for the efficacy of BEV; 4 partial response, 1 stable disease, and 1 progressive disease. There was no any central nervous hemorrhage. Conclusion?The administration of BEV for non-squmous NSCLC patients with brain metastase was safe and effective. MITSUHIRO FUJII1, SHIN-ICHIRO IWAKAMI1, HIROAKI IHARA1, MUNECHIKA HARA1, NAOKO Depsipeptide IWAKAMI1, TOSHIJI ISHIWATA1, KAZUHISA TAKAHASHI2 1Department of Respiratory Medicine, Juntendo University Shizuoka Hospital, Shizuoka, Japan, 2Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan Background?The malignant pleural effusion indicates not only poor prognosis but also impairment of their quality of life (QOL) for patients with non-small cell lung cancer. It has been considered that acceleration of vascular permeability caused by vascular endothelial growth factor (VEGF) produced by cancer cells may be cause of malignant pleural effusion formation. The aim of this study is to evaluate efficacy and safety of bevacizumab, an anti-VEGF antibody, containing chemotherapy in patients with non-small cell lung cancer with malignant pleural effusion.